Related Experiment Video
Updated: Jul 5, 2026
08:23
Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
Gardos pathway to sickle cell therapies?
1Cincinnati Children's Hospital Medical Center, USA.
Blood
|April 25, 2008
Summary
Senicapoc, a Gardos channel inhibitor, offers new hope for sickle cell disease patients by reducing dehydrated cells and improving hemoglobin levels. This treatment also effectively diminishes red blood cell breakdown, offering a promising therapeutic avenue.
Area of Science:
- Hematology
- Molecular Biology
- Pharmacology
Background:
- Sickle cell disease (SCD) is a debilitating genetic disorder characterized by abnormal hemoglobin and red blood cell dysfunction.
- Dehydrated red blood cells and hemolysis are key pathological features of SCD, contributing to vaso-occlusion and anemia.
- Gardos channel activation plays a critical role in red blood cell dehydration in SCD.
Discussion:
- Senicapoc, a selective Gardos channel inhibitor, was investigated for its therapeutic potential in SCD patients.
- The study evaluated the effects of senicapoc on red blood cell hydration, hemoglobin levels, and hemolysis.
- Treatment with senicapoc demonstrated significant improvements in these key pathological markers.
Key Insights:
- Senicapoc treatment led to a reduction in the number of dehydrated red blood cells in SCD patients.
- Hemoglobin levels were observed to increase following senicapoc administration.
- Diminished hemolysis was a notable outcome, suggesting a protective effect on red blood cells.
Outlook:
- Senicapoc represents a promising therapeutic strategy for managing sickle cell disease.
- Further clinical trials are warranted to confirm the long-term efficacy and safety of senicapoc.
- Targeting Gardos channels offers a novel approach to ameliorating SCD pathophysiology.
Related Concept Videos
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
01:49Multiple Allele Traits
The Concept of Multiple Allelism
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
01:28Role of Hematopoietic Growth Factors
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
01:23Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:21Hematopoiesis
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...